A Phase 2 Multicenter Single-arm Study to Assess the Safety Feasibility and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-144) Followed by IL-2 for Treatment of Metastatic Melanoma

Brief description of study

If you have been diagnosed with metastatic melanoma that has gotten worse after previous treatment, you may qualify for this phase II study evaluating the investigational drug LN-144. The main goal of this study is to find out if study drug LN-144 is safe for patients with metastatic melanoma.


Clinical Study Identifier: s16-00804
ClinicalTrials.gov Identifier: NCT02360579
Principal Investigator: Anna C Pavlick
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.